Page 65 - Read Online
P. 65

Page 6 of 13                              Eng et al. J Cancer Metastasis Treat 2019;5:69  I  http://dx.doi.org/10.20517/2394-4722.2019.021

               Table 1. MiRNAs and their effects on autophagy and metastasis
                                                      Effect in Autophagy
                miRNA        Action   Gene target   Mechanism of action  Expression status in cancer Effect in metastasis
                miR-100    Activator [30]  mTOR  Activates ULK1 initiation  Upregulated [30]  Activator [30,31]
                miR-146a   Activator [32]  BCL2  Activates PI3K III nucleation  Upregulated [33]  Activator [33,34]
                miR-23b    Inhibitor [35]  HMGB2  Inhibits PI3K III nucleation  Downregulated [35,36]  Inhibitor [36]
                                       ATG12    Inhibits ATG12 conjugation
                miR-24     Inhibitor [37]  BCL2  Inhibits PI3K III nucleation  Downregulated [38]  Inhibitor [38]
                                       ATG4     Inhibits LC3 conjugation
                miR-26a/b  Inhibitor [39]  ULK1  Inhibits ULK1 initiation  Downregulated [39,40]  Inhibitor [40]
                miR-30a    Inhibitor [41]  Beclin1  Inhibits PI3K III nucleation  Downregulated [42]  Inhibitor [42]
                miR-34     Inhibitor [43,44]  HMGB1  Inhibits PI3K III nucleation  Downregulated [45]  Inhibitor [46]
                                       ATG9a    Inhibits ATG9 cycling
                miR-125a   Inhibitor [47]  UVRAG  Inhibits PI3K III nucleation  Downregulated [48]  Inhibitor [48]
                miR-141    Inhibitor [49]  SIRT1  Inhibits ATG12 and LC3   Downregulated [50]  Inhibitor [50,51]
                                                conjugation
                miR-143    Inhibitor [52]  ATG2B  Inhibits ATG9 cycling   Downregulated [53]  Inhibitor [53]
                miR-199    Inhibitor [54,55]  ATG14  Inhibits PI3K III nucleation  Downregulated [56]  Inhibitor [56]
                                       Rab7A    Inhibits autophagosome and
                                                lysosome fusion
                miR-200    Inhibitor [57]  ATG12  Inhibits ATG12 conjugation  Downregulated [58]  Inhibitor [58,59]
                miR-520    Inhibitor [60]  ATG7  Inhibits ATG12 and LC3   Downregulated [60]  Inhibitor [61]
                                                conjugation
                miR-21     Inhibitor [62,63]  Rab11A  Inhibits ULK1 initiation and ATG9   Upregulated [64]  Activator [64]
                                       PTEN     cycling
                miR-29a    Inhibitor [65]  ATG9A  Inhibits ATG9 and its cycling  Upregulated [66]  Activator [66]
                miR-93     Inhibitor [67,68]  PTEN  Inhibits ULK1 initiation  Upregulated [67]  Activator [67,69]
                                       ATG16L1  Inhibits ATG12 conjugation
                miR-214    Inhibitor [70]  PTEN  Inhibits ULK1 initiation  Upregulated [71]   Activator [71]
                                       ATG12    Inhibits ATG12 conjugation
                miR-221/222  Inhibitor [72]  ATG12  Inhibits ATG12 conjugation  Upregulated [72,73]  Activator [73]
                let-7      Activator [74]  mTOR  Activate ULK1 initiation  Downregulated [75]  Inhibitor [75]
                miR-7      Activator [76]  mTOR  Activates ULK1 initiation  Downregulated [77]  Inhibitor [77]
                miR-16     Activator [78]  mTOR  Activates ULK1 initiation  Downregulated [79]  Inhibitor [79]
                miR-205    Activator [80,81]  PTEN  Activates ULK1 intiation  Downregulated [82]  Inhibitor [82]

               these oncomiRs provides several advantages to the invading cancer cells. Firstly, an increase in autophagy
               flux helps DTCs to resist anoikis following detachment from the primary tumor as well as to enable
               DTCs to gain access to nutrients to survive the arduous journey of traversing to distant organs/tissues.
               In addition, they concurrently change gene expression patterns in the cancer cells to allow these cells to
               become mesenchymal and thus more motile to invade distant sites.

               Apart from oncomiRs, the loss of tumor-suppressive miRNAs has also been shown to drive cell
               invasion and migration [Figure 1]. Several autophagy-inhibiting miRNAs, namely, miR-23b, miR-24,
               miR-26, miR-30a, miR-34, miR-125a, miR-141, miR-143, miR-199, miR-200 and miR-520 are found to be
               downregulated in cancer. Notably, these miRNAs are also known MET effectors [35-43,45-61,85,86] . As opposed to
               the primary role(s) of oncomiRs, we speculate that the loss of these miRNAs allows for higher autophagy
               flux and suppression of MET in the DTCs to help them adapt to unfavorable settlement sites.

               Intriguingly, there exists a group of miRNAs that appear to block autophagy and yet promote EMT. These
               include oncogenic miR-21, miR-29a, miR-93, miR-214 and the miR-221/222 cluster that are highly expressed
               in cancer [Figure 2] [62-73,87] . It seems counter-intuitive that successful distant organ/tissue invasion can be
               achieved for cancer cells without autophagy, but it remains plausible that the effects of these miRNAs might
               be context-dependent. For example, overexpression of miR-21 and miR-93 have been shown to induce
               metastasis by targeting PTEN [64,69] , which in turn may promote the blockade of autophagy via activating
               the PI3K-Akt-mTOR signaling cascade. Since one miRNA can target many different genes, the biological
   60   61   62   63   64   65   66   67   68   69   70